Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.
U.S. doubles reward for Maduro, citing 'narco-state' as Venezuela's leader remains openly in the country.
Tesla shifts AI strategy, ending Dojo project and partnering with Samsung for next-gen self-driving chips amid challenges in electric vehicle sales and robotaxi rollout.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise on expanded insurer coverage for new drug Yeztugo.
U.S. doubles reward for Maduro, citing 'narco-state' as Venezuela's leader remains openly in the country.
Tesla shifts AI strategy, ending Dojo project and partnering with Samsung for next-gen self-driving chips amid challenges in electric vehicle sales and robotaxi rollout.